2023
Influence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: A pilot study
Taylor H, Alhasan S, Saleem M, Poole S, Jiang F, Longbrake E, Bove R. Influence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: A pilot study. Multiple Sclerosis And Related Disorders 2023, 77: 104864. PMID: 37480738, PMCID: PMC11090415, DOI: 10.1016/j.msard.2023.104864.Peer-Reviewed Original ResearchConceptsContinuous oral contraceptivesOral contraceptivesOC usersMenstrual cycleSymptom fluctuationsPilot studyTwo-centre pilot studyRegular menstrual cyclesHormonal contraceptive useIntrauterine device usersMenstrual cycle phaseFuture confirmatory studiesMedian EDSSMean ageGeneralized symptomsHormonal measurementsPerimenstrual periodSymptom SurveyContraceptive useLarge cohortLuteal periodClinical practiceContraceptive choicesParticipant retentionSymptom severity
2022
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Freeman L, Longbrake E, Coyle P, Hendin B, Vollmer T. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis. CNS Drugs 2022, 36: 1285-1299. PMID: 36350491, PMCID: PMC9645316, DOI: 10.1007/s40263-022-00965-7.Peer-Reviewed Original ResearchConceptsRelapsing-remitting multiple sclerosisHigh-efficacy therapiesMultiple sclerosisClinical benefitEarly treatmentRecent international consensus guidelinesLong-term clinical outcomesAvailable treatment optionsInternational consensus guidelinesTreatment-naïve individualsMechanism of actionDMT optionsMS careDisease courseClinical outcomesConsensus guidelinesTherapy optionsTreatment optionsNeurological damageTreatment strategiesEscalation approachClinical practiceUS FoodDrug AdministrationPatientsEffect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis.
Daboul L, O'Donnell CM, Cao Q, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree BAC, Freeman L, Henry RG, Longbrake EE, Nakamura K, Oh J, Papinutto N, Pelletier D, Samudralwar RD, Suthiphosuwan S, Schindler MK, Sotirchos ES, Sicotte NL, Solomon AJ, Shinohara RT, Reich DS, Ontaneda D, Sati P. Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis. American Journal Of Roentgenology 2022, 220: 115-125. PMID: 35975888, PMCID: PMC10016223, DOI: 10.2214/ajr.22.27731.Peer-Reviewed Original ResearchConceptsWhite matter lesionsCentral vein signGBCA useMultiple sclerosisMS diagnosisVein signPostcontrast imagesGadolinium-based contrast agent administrationPilot study cohortDiagnostic performanceContrast agent administrationMcDonald criteriaInvestigational trialsStudy cohortMatter lesionsClinical dataClinical impactBrain MRIClinical practiceAgent administrationDiagnostic biomarkersMRI biomarkersPostcontrast FLAIRPrecontrast imagesSecondary analysis
2017
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS
Baldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT. Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS. Multiple Sclerosis Journal 2017, 24: 1347-1355. PMID: 28766993, DOI: 10.1177/1352458517721357.Peer-Reviewed Original ResearchConceptsDisability Status ScaleStatus ScaleClinical practiceExpanded Disability Status ScaleMultiple sclerosis clinical trialsMultiple sclerosis clinical practiceCross-sectional comparisonCombiRx trialDisability scoresClinical trialsPilot cohortEDSSClinical monitoringPatient careClinical settingPatientsTrialsDisabilityFunctional systemsUseful measureScoringStandard measuresCohortCare
2016
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
Longbrake EE, Cross AH, Salter A. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice. Multiple Sclerosis Journal - Experimental Translational And Clinical 2016, 2: 2055217316677868. PMID: 28280599, PMCID: PMC5340186, DOI: 10.1177/2055217316677868.Peer-Reviewed Original ResearchDisease-modifying therapiesMultiple sclerosis activityInjectable disease-modifying therapiesOral disease-modifying therapiesMultiple sclerosisInjectable therapiesBaseline differencesClinical practiceRetrospective cohort studyProportional hazards modelDrug discontinuationCohort studyDiscontinuation ratesTreatment groupsHazards modelSclerosisPatientsTherapyRelative efficacyTolerabilityFurther studiesHigher proportionEfficacyExpert opinionTreatment